Processa management is available for one-on-one meetings with potential investors and partners in
Details of Processa’s presentation at the Biotech Showcase are as follows:
Date:
Time:
Track: Yosemite A (Ballroom Level)
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses its Regulatory Science Approach criteria when selecting and developing drugs to achieve high-value milestones effectively and efficiently. Current clinical pipeline programs include: Next Generation Capecitabine PCS6422 (metastatic colorectal cancer, breast cancer), PCS3117 (pancreatic and other cancers), PCS11T (small cell lung and other cancers), PCS12852 (gastroparesis, functional constipation), and PCS499 (ulcerative necrobiosis lipoidica). Members of the Processa development team have been involved with more than 30 approvals for indications in almost every division of the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit our website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by
For More Information:
(301) 651-4256
mfloyd@processapharma.com
(925) 683-3218
plin@processapharma.com
![](https://ml.globenewswire.com/media/YmQ1ODYwMTEtNjgwNS00YzZlLWI4NTYtNmI4ZDg5OGMzZmNjLTUwMDA0NjUzNQ==/tiny/Processa-Pharmaceuticals-Inc-.png)
2023 GlobeNewswire, Inc., source